{"id":25245,"date":"2023-10-12T16:45:34","date_gmt":"2023-10-12T11:15:34","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25245"},"modified":"2024-09-18T15:14:48","modified_gmt":"2024-09-18T09:44:48","slug":"medtech-news-for-everly-sanguina-biotronik","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik","title":{"rendered":"B. Braun\u2019s Introcan Safety 2 IV Catheter; Everly Health\u2019s At-Home Collection Kidney Health Test; FDA Clearance to Sanguina\u2019s AnemoCheck Home; FDA Clearance for the DePuy\u2019s TriALTIS\u2122 Spine System; Biotronik\u2019s Spinal Cord Stimulation Tech; Contego Medical\u2019s Performance III Direct Transcarotid Access Stenting Trial"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0bafa86c160\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0bafa86c160\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik\/#B_Braun_Launched_Introcan_Safety%C2%AE_2_IV_Catheter_with_Multi-Access_Blood_Control_Designed_to_Protect_Clinicians_Every_Time_the_Hub_is_Accessed\" >B. Braun Launched Introcan Safety\u00ae 2 IV Catheter with Multi-Access Blood Control Designed to Protect Clinicians Every Time the Hub is Accessed<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik\/#Everly_Health_Launched_Comprehensive_At-Home_Collection_Kidney_Health_Test_to_Address_Chronic_Kidney_Disease\" >Everly Health Launched Comprehensive At-Home Collection Kidney Health Test to Address Chronic Kidney Disease&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik\/#Sanguina_Announced_US_FDA_Clearance_for_AnemoCheck_Home\" >Sanguina Announced US FDA Clearance for AnemoCheck Home<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik\/#DePuy_Synthes_Received_US_FDA_Clearance_for_the_TriALTIS%E2%84%A2_Spine_System_and_Navigation_Enabled_Instruments\" >DePuy Synthes Received US FDA Clearance for the TriALTIS\u2122 Spine System and Navigation Enabled Instruments&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik\/#Biotronik_Announced_Positive_Data_for_its_Spinal_Cord_Stimulation_Tech\" >Biotronik Announced Positive Data for its Spinal Cord Stimulation Tech&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik\/#Contego_Medical_Announced_Start_of_Enrollment_in_Performance_III_Direct_Transcarotid_Access_Stenting_Trial\" >Contego Medical Announced Start of Enrollment in Performance III Direct Transcarotid Access Stenting Trial&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-b-braun-launched-introcan-safety-2-iv-catheter-with-multi-access-blood-control-designed-to-protect-clinicians-every-time-the-hub-is-accessed\"><span class=\"ez-toc-section\" id=\"B_Braun_Launched_Introcan_Safety%C2%AE_2_IV_Catheter_with_Multi-Access_Blood_Control_Designed_to_Protect_Clinicians_Every_Time_the_Hub_is_Accessed\"><\/span><strong>B. Braun Launched Introcan Safety\u00ae 2 IV Catheter with Multi-Access Blood Control Designed to Protect Clinicians Every Time the Hub is Accessed<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> October 11, 2023, B. Braun Medical Inc. (B. Braun)<\/strong>, a leader in smart infusion therapy, announced the launch of its new <strong>Introcan Safety\u00ae 2 IV Catheter with Multi-Access Blood Control<\/strong>.&nbsp;<\/p>\n\n\n\n<p>The most recent addition to B. Braun&#8217;s extensive range of passive needlestick avoidance catheters is the Introcan Safety 2 IV Catheter. Every time the hub is accessed, a blood control mechanism shields clinicians from blood exposure in addition to automatic needlestick protection. Lowering the chance of coming into contact with bloodborne pathogens during the IV procedure.<\/p>\n\n\n\n<p>An essential component of infusion therapy is IV access, and needlestick injuries are still a major danger that doctors must deal with regularly, putting them at risk for exposure to bloodborne infections. Research indicates that fully automatic, passive safety devices reduce needlestick injuries three times better than manually sliding shields and twice as well as semi-automatic &#8220;push button&#8221; safety shields. A fully automatic passive safety device protects clinicians with the Introcan Safety 2 Catheter.<\/p>\n\n\n\n<p>Blood exposure on the mucocutaneous layer as a result of catheter hub spillage is a hazard in addition to needlestick injuries. It has been demonstrated that blood-control IV catheters greatly lower the risk of blood exposure and the cleaning effort involved. Furthermore, a survey&#8217;s findings suggest that the time and materials needed for blood cleanup could be less expensive. The multi-access blood control function of the new Introcan Safety 2 Catheter operates numerous times, assisting in minimizing blood exposure and spillage throughout the IV procedure.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;Appropriate device selection is key to achieving successful PIVC outcomes,&#8221;<\/em> <strong>said Chad Laity, Director of Marketing, Vascular Access, IV Systems and Securement. Chad added, <\/strong><em>&#8220;The newly launched Introcan Safety 2 IV Catheter with Multi-Access Blood Control provides clinicians with another option when choosing the right device for their patients. When combined with our Peripheral Advantage\u00ae Program, our technology and solutions are designed to facilitate the best possible outcomes around vascular access care.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>As per DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/peripherally-inserted-central-catheter-picc-devices-market\"><strong>Peripherally Inserted Central Catheter Devices<\/strong> <strong>Market<\/strong><\/a><strong>\u201d<\/strong> report, the Peripherally Inserted Central Catheter (PICC) Devices market was valued at <strong>USD 976.13 million<\/strong> in 2022, growing at a <strong>CAGR <\/strong>of <strong>5.29%<\/strong> during the forecast period from 2023 to 2028 to reach <strong>USD 1,326.59 million<\/strong> by 2028. The demand for peripherally inserted central catheter devices is primarily being boosted owing to key factors such as the <a href=\"https:\/\/www.delveinsight.com\/blog\/most-common-cancers-2\"><strong>increasing incidence of cancers<\/strong><\/a>, and infectious diseases, among others, technological advancements in product portfolio, and proper reimbursement coupled with increasing product launches, thus creating a positive market growth for the Peripherally Inserted Central Catheter (PICC) Devices market during the forecast period from 2023-2028.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-everly-health-launched-comprehensive-at-home-collection-kidney-health-test-to-address-chronic-kidney-disease-nbsp\"><span class=\"ez-toc-section\" id=\"Everly_Health_Launched_Comprehensive_At-Home_Collection_Kidney_Health_Test_to_Address_Chronic_Kidney_Disease\"><\/span><strong>Everly Health Launched Comprehensive At-Home Collection Kidney Health Test to Address Chronic Kidney Disease&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> October 5, 2023<\/strong>, <strong>Everly Health,<\/strong> a digital health company at the forefront of remote diagnostics-driven care, launched a comprehensive at-home collection kidney health test for health plans and employers to expand access to prevention, diagnosis, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-ckd-pipeline-insight\"><strong>treatment of chronic kidney disease (CKD)<\/strong><\/a>.<\/p>\n\n\n\n<p>The Everly Health At-Home Collection Kidney Health Test combines the estimation of kidney function through blood collection, estimated glomerular filtration rate (eGFR), and kidney function assessment through urine collection using the urinary albumin-to-creatinine ratio (UACR). Everly Health ensures that tests reach or surpass the accuracy of conventional laboratory tests by using cutting-edge technology and processing samples at labs approved by CAP and CLIA. When compared to normal collection procedures, the Everly Health Kidney Health Test collection methods have a correlation of above 98.6%.<\/p>\n\n\n\n<p>By facilitating testing and meeting the 2024 KED HEDIS measure, the kidney health test with at-home collection seeks to reduce lifetime expenses related to diabetes and Chronic Kidney Disease.<\/p>\n\n\n\n<p>According to Everly Health data, Medicare costs related to chronic kidney disease (CKD) may be lowered by 74%, or USD 63.2 billion, if kidney illness is detected early. Everly Health&#8217;s diagnostics-driven remote care model makes it simple to improve health outcomes at significantly lower costs to both patient and provider, as health plans strive to close Healthcare Effectiveness Data and Information Set (HEDIS) measures and raise The Centers for Medicare &amp; Medicaid Services (CMS) Star Ratings.<\/p>\n\n\n\n<p>With the help of Everly Health&#8217;s in-house technology platform, health plan administrators can easily and digitally monitor the whole duration of preventative screening programs, from reporting to monitoring. The procedure is straightforward for patients: they simply pick up their user-friendly at-home test kit, gather a sample, and return it in a pre-paid envelope.<\/p>\n\n\n\n<p>Electronically sent test results, shipment and processing updates, and warnings of any possible anomalies are sent to participants. If necessary, participants also receive practical next actions from a healthcare professional.<em>&nbsp;<\/em><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cKidney disease affects 37 million adults in the United States but 90% are unaware they even have it which makes it a silent killer,\u201d<\/em> <strong>said Dr. Liz Kwo, MD, MPH, MBA, Everly Health Solutions Chief Commercial Officer. Dr. Liz added, <\/strong><em>\u201cWe have an opportunity to significantly change the course of chronic kidney disease in the United States by working to ensure early detection is available to people through the testing they need to protect their kidney health.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-chronic-renal-failure-market\"><strong>Chronic Kidney Disease Market<\/strong><\/a><strong>\u201d<\/strong> report, the Chronic Kidney Disease Market is expected to grow at a <strong>CAGR<\/strong> of <strong>6.6%<\/strong> during the forecast period from 2023 to 2028. Factors such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-chronic-renal-failure-epidemiology-forecast\"><strong>increasing incidences of chronic kidney disease<\/strong><\/a>, technological advancements in diagnostic tests for kidney diseases, and the increasing need for early detection are promoting market growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanguina-announced-us-fda-clearance-for-anemocheck-home\"><span class=\"ez-toc-section\" id=\"Sanguina_Announced_US_FDA_Clearance_for_AnemoCheck_Home\"><\/span><strong>Sanguina Announced US FDA Clearance for AnemoCheck Home<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> October 4, 2023<\/strong>, <strong>Sanguina, Inc. (Sanguina)<\/strong>, a leading biotech company, announced the US Food and Drug Administration (FDA) clearance of <strong>AnemoCheck Home<\/strong>, the only FDA-cleared home hemoglobin test kit available in the United States.<\/p>\n\n\n\n<p>With the revolutionary AnemoCheck Home test, people with anemia caused by nutritional deficiencies (such as iron, vitamin B12, or folate deficiency), sickle cell disease, or thalassemia can now easily check their hemoglobin levels in the comfort of their own homes. The test is an <a href=\"https:\/\/www.delveinsight.com\/report-store\/in-vitro-diagnostics-market\"><strong>in vitro diagnostic tool<\/strong><\/a> that can only be obtained with a prescription, guaranteeing proper medical supervision and direction.<\/p>\n\n\n\n<p>With AnemoCheck Home, users may perform a quick fingerstick blood test to acquire precise hemoglobin level readings. The user sticks their finger, draws blood into a sample collecting tube, and then attaches the test body to the test cap. After that, the test is shaken to mix the blood. The color on a color card corresponds to the hemoglobin level after two minutes. There is no need for any additional equipment, and the test is disposable.<\/p>\n\n\n\n<p>By utilizing the most recent developments in medical technology, AnemoCheck Home guarantees accurate and dependable findings, giving consumers the ability to take charge of their anemia treatment.&nbsp;<\/p>\n\n\n\n<p>Easy-to-follow instructions and all necessary supplies are included in the kit to ensure a safe and effective fingerstick test.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Erika Tyburski, CEO of Sanguina commented,<em> <\/em><\/strong><em>&#8220;Our team at Sanguina is proud to introduce AnemoCheck Home as a game-changer for at-home anemia testing. With this FDA clearance, we are excited to provide people who have anemia with a convenient, accurate, and accessible tool to monitor their hemoglobin levels at home.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201cHemoglobin Testing Market Insights and Competitive Landscape\u201d <\/strong>report, the global hemoglobin testing market is estimated to grow at a <strong>CAGR<\/strong> of <strong>7.10%<\/strong> during the forecast period from 2023 to 2028. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/anemia-market\"><strong>rising prevalence of chronic diseases such as anemia<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-market\"><strong>diabetes<\/strong><\/a> is boosting the global hemoglobulin testing market. Furthermore, factors such as good reimbursement for hemoglobin testing under various health insurance policies are catalyzing market expansion. Furthermore, factors such as improved health infrastructure, rising per capita healthcare expenditure, rising awareness for blood-related disorders, an aging population, technological improvements, and so on are expected to boost the global hemoglobin testing market in the approaching years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-depuy-synthes-received-us-fda-clearance-for-the-trialtis-spine-system-and-navigation-enabled-instruments-nbsp\"><span class=\"ez-toc-section\" id=\"DePuy_Synthes_Received_US_FDA_Clearance_for_the_TriALTIS%E2%84%A2_Spine_System_and_Navigation_Enabled_Instruments\"><\/span><strong>DePuy Synthes Received US FDA Clearance for the TriALTIS\u2122 Spine System and Navigation Enabled Instruments&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>October<\/strong> <strong>9, 2023,<\/strong> <strong>Johnson &amp; Johnson MedTech <\/strong>announced that <strong>DePuy Synthes<\/strong>, The Orthopaedics Company of Johnson &amp; Johnson secured 510(k) clearances from the U.S. Food and Drug Administration (FDA) for the <strong>TriALTIS\u2122 Spine System and TriALTIS\u2122 Navigation Enabled Instruments.<\/strong><\/p>\n\n\n\n<p>With its superior instrumentation and complete implant portfolio, the TriALTIS\u2122 Spine System is a next-generation posterior thoracolumbar pedicle screw system that can be integrated with supporting technologies.<\/p>\n\n\n\n<p>Drills, taps, and screwdrivers that may be used manually or with power for both navigated and non-navigated applications are examples of TriALTIS\u2122 Navigation Enabled Instruments.<\/p>\n\n\n\n<p>The TriALTIS\u2122 Spine System combines a revolutionary implant portfolio with a digital environment to meet unmet clinical needs and assist surgeons in treating complicated spine disorders, such as degenerative, tumor, trauma, and deformity pathologies, with more consistent outcomes.<\/p>\n\n\n\n<p>With a primary focus on performance and a consistent user experience, the TriALTIS\u2122 Spine System was designed, building upon a tradition of dependable thoracolumbar solutions and knowledge. The TriALTIS\u2122 Spine System&#8217;s forward-thinking and inclusive design philosophy allows for seamless integration with robotically assisted solutions, power, navigation, and cement augmentation.<\/p>\n\n\n\n<p>According to DePuy Synthes, the TriALTIS\u2122 Spine System will be accessible in the United States by 2024.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWhen it comes to treating complex spinal pathologies, each patient is different, and each case requires its own unique treatment decisions,\u201d <\/em>said <strong>Daniel Sciubba, MD, MBA, and Chair &amp; Professor of Neurosurgery at Northwell Health\/Hofstra. Daniel added, <\/strong><em>\u201cThe TriALTIS\u2122 Spine System offers a comprehensive implant portfolio that complements different anatomies and procedures and can help to streamline surgical workflows and enable intraoperative flexibility \u2013 all with the potential to improve clinical experiences.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;The TriALTIS\u2122 Spine System will be our premier pedicle screw platform designed to work seamlessly across our entire DePuy Synthes portfolio of enabling technology solutions,&#8221; <\/em>said <strong>Russell Powers, Worldwide President, Spine, DePuy Synthes. Russell commented,<\/strong> \u201c<em>Johnson &amp; Johnson MedTech is proud to deliver this exciting innovation that can help facilitate the surgical treatment of spinal degeneration and deformity to improve fixation, drive better patient outcomes, and potentially reduce the clinical and economic burden associated with the current standard of care. DePuy Synthes has been a leader in the complex spine space for over 35 years, and the launch of the TriALTIS\u2122 Spine System will mark a critical milestone towards our vision to continue this legacy long into the future.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-surgery-devices-market\"><strong>Spinal Surgery Devices Market<\/strong><\/a>\u201d report, the global spinal surgery devices market is estimated to grow at a <strong>CAGR<\/strong> of <strong>5.65%<\/strong> during the forecast period from 2023 to 2028. The spinal surgery devices market is observing remarkable market growth owing to various factors such as the subsequent <a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-muscular-atrophy-market\"><strong>rise in spinal disorders<\/strong><\/a> across the globe, <a href=\"https:\/\/www.delveinsight.com\/report-store\/traumatic-brain-injury-market\"><strong>increasing road accidents<\/strong><\/a>, and increasing demand for minimally invasive surgical procedures among others. Further, the increasing demand for technologically advanced spinal surgery devices in the market will also spur market growth in the forthcoming years. Additionally, a rise in spending on spinal surgery products along with the increasing product launches and approvals, and other factors will create a requisite for the spinal surgery devices in the market. Therefore, the market for spinal surgery devices is estimated to grow at a substantial CAGR during the forecast period from 2023 to 2028.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-biotronik-announced-positive-data-for-its-spinal-cord-stimulation-tech-nbsp\"><span class=\"ez-toc-section\" id=\"Biotronik_Announced_Positive_Data_for_its_Spinal_Cord_Stimulation_Tech\"><\/span><strong>Biotronik Announced Positive Data for its Spinal Cord Stimulation Tech&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> October 5, 2023, Biotronik <\/strong>announced positive results from a clinical trial for its <strong>Neuro Prospera spinal cord stimulation (SCS) system<\/strong>.&nbsp;<\/p>\n\n\n\n<p>The Neuro Prospera system&#8217;s Resonance multiphase stimulating paradigm is evaluated in the BENEFIT-02 trial. It examined the stimulator&#8217;s efficacy and safety in <a href=\"https:\/\/www.delveinsight.com\/report-store\/neuropathic-pain-pipeline-insight\"><strong>treating patients with persistent pain<\/strong><\/a>.&nbsp;<\/p>\n\n\n\n<p>Resonance employs a proprietary integrated circuit architecture and uses less power than other SCS therapies currently on the market, according to Biotronik. It provides the spinal cord with a continuous, momentarily, and spatially dispersed therapeutic pulse rhythm.<\/p>\n\n\n\n<p>Participants in Biotronik&#8217;s prospective, multicenter, randomized, single-blind feasibility trial comprised those who had persistent leg or low back discomfort. An initial numerical rating scale (NRS) for total pain intensity higher than or equal to six was provided. Patients were randomly assigned to multiphase therapy by Biotronik following a successful commercial SCS trial.&nbsp;<\/p>\n\n\n\n<p>After washout, patients had 11\u201312 days of testing using an experimental external pulse generator and their current leads for therapy.<\/p>\n\n\n\n<p>There was no statistically significant difference in the mean NRS reduction or percent pain alleviation between multiphase therapies in the 65 patients who finished the research. Compared to commercial SCS, multiphase therapy was reported by 63.9% of participants to provide better pain alleviation in the at-home environment. They also mentioned an improvement in their level of physical activity and average sleep quality.<\/p>\n\n\n\n<p>According to Biotronik, there were very few adverse effects and none that the investigators deemed to be &#8220;serious.&#8221;<\/p>\n\n\n\n<p>The BENEFIT-02 study is a component of the Prospera SCS system research program from Biotronik. The FDA approved Prospera earlier this year. Additionally, the business reported encouraging preliminary results from its lengthy BENEFIT-03 research. Prospera is evaluated by BENEFIT-03 using remote programming, automatic daily objective device monitoring, and resonance multiphase stimulation. Significant pain reduction was observed in both in-clinic and at-home settings with less severe disability, according to interim six-month results.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cAs we await additional data from our BENEFIT-03 study, we\u2019re excited to see these initial data on the long-term effects of our SCS system,\u201d<\/em> said <strong>Biotronik Neuro President Todd Langevin<\/strong>. Todd added, <em>\u201cWe developed Prospera to offer patients sustainable pain relief \u2013 and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-cord-stimulator-market\"><strong>Spinal Cord Stimulators (SCS) Market<\/strong><\/a>\u201d report, the global spinal cord stimulators (SCS) market was valued at <strong>USD 2.25 billion<\/strong> in 2022, growing at a <strong>CAGR<\/strong> of <strong>8.70%<\/strong> during the forecast period from 2023 to 2028 to reach <strong>USD 3.72 billion<\/strong> by 2028. The demand for spinal cord stimulators (SCS) is primarily attributed to the <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-pain-market\"><strong>growing number of patients with chronic pain<\/strong><\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/neuropathic-pain-market\"><strong>neuropathic pain<\/strong><\/a> in the shoulder, legs, and knee. The technologically advanced devices that are non-invasive, eliminate targeted pains, and cause a reduction in patient discomfort, with no side effects are likely responsible for a boost in the global spinal cord stimulators (SCS) market growth. Moreover, favorable government regulations for commercialization and launching products in the market and the rising geriatric population are some of the factors responsible for propelling the growth of the spinal cord stimulators (SCS) market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-contego-medical-announced-start-of-enrollment-in-performance-iii-direct-transcarotid-access-stenting-trial-nbsp\"><span class=\"ez-toc-section\" id=\"Contego_Medical_Announced_Start_of_Enrollment_in_Performance_III_Direct_Transcarotid_Access_Stenting_Trial\"><\/span><strong>Contego Medical Announced Start of Enrollment in Performance III Direct Transcarotid Access Stenting Trial&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>October 6, 2023<\/strong>, Contego Medical Inc., a company dedicated to improving patient outcomes and procedural efficiency in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-vascular-devices-market\"><strong>treatment of carotid and peripheral vascular disease<\/strong><\/a>, announced enrollment of the first patient in the PERFORMANCE III Trial.<\/p>\n\n\n\n<p>Aiming to further assess the safety and efficacy of the Neuroguard IEP\u00ae Direct System, a carotid stent system intended for direct transcarotid access, PERFORMANCE III is a prospective, multicenter study. This research is an extension of the fully enrolled PERFORMANCE II study of the Neuroguard IEP System, which assessed the identical stent inserted with either transradial or transfemoral percutaneous access. This research is an extension of the fully enrolled PERFORMANCE II study of the Neuroguard IEP System, which assessed the identical stent inserted with either transradial or transfemoral percutaneous access.<\/p>\n\n\n\n<p>The US Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) for the conduct of the PERFORMANCE II and PERFORMANCE III trials.&nbsp;<\/p>\n\n\n\n<p>Utilizing Contego Medical&#8217;s integrated embolic protection (IEP) technology, the Neuroguard IEP and Neuroguard IEP Direct Systems provide enhanced safety during stent placement and balloon dilation. IEP technology is a unique platform featuring a micro-filter integrated into the delivery catheter. By capturing the micro-emboli that other protection methods miss, the micro-filter provides doctors with the procedural confidence that comes with improved stroke protection when treating patients. An innovative single-access-point blood flow reversal technology made especially for direct transcarotid access is also included with the Neuroguard IEP Direct technology.&nbsp;<\/p>\n\n\n\n<p>By combining the stent, balloon, and micro-filter into one 3-in-1 catheter, the Neuroguard system reduces the need for several catheter exchanges and enhances treatment effectiveness. In addition, Neuroguard makes use of the tried-and-true FlexRing<sup>TM<\/sup> stent technology, which combines the advantages of open and closed cell stents with the long-term material performance of nitinol.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;At Contego, we&#8217;re driven to improve patient outcomes and will continue to collect robust clinical data to build upon the unprecedented stroke protection results already demonstrated with our IEP (integrated embolic protection) platform technology in the PALADIN and PERFORMANCE I studies,&#8221;<\/em> said <strong>Dr. Ravish Sachar, CEO of Contego Medical.&nbsp;<\/strong><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>Stacy Enxing Seng, Operating Partner at Lightstone Ventures and Chairman of the Board of Contego Medical, added: <\/strong><em>&#8220;Contego is committed to advancing care for patients by providing best-in-class stent, balloon, and filter technology so all physicians in the vascular community have the best tools at their disposal, no matter how they choose to access the carotid artery.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;We look forward to studying the Neuroguard IEP Direct System and determining its potential as a new option for patients with carotid artery stenosis,&#8221; <\/em>said <strong>Dr. Sean Lyden, Chairman of the Department of Vascular Surgery at Cleveland Clinic and Co-National Principal Investigator of the PERFORMANCE III Trial.<\/strong><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;I have no doubt the Neuroguard IEP Direct system will elevate the standard of care for carotid artery stenosis patients,&#8221;<\/em> commented <strong>Dr. Robert Mendes, a vascular surgeon at the University of North Carolina Rex Hospital, who treated the first patient in the PERFORMANCE III study<\/strong>. Dr. Robert mentioned, <em>&#8220;Its safety is unmatched, and it is simple and efficient to operate. This is an across-the-board advancement in technology in every aspect of the system, from the optimized direct access kit to the blood flow reversal system to the added integrated embolic protection (IEP). It&#8217;s a 3-in-1 leap forward in catheter design.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to<strong> <\/strong>DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/stents-market\"><strong>Stents Market<\/strong><\/a>\u201d report, the global Stents market is estimated to grow at a <strong>CAGR<\/strong> of <strong>5.61%<\/strong> during the forecast period from 2023 to 2028. The stents market is witnessing positive growth owing to factors such as the increasing prevalence of chronic diseases, rise in the geriatric population, increasing demand for minimally invasive procedures, and increase in unhealthy lifestyles, all factors contributing to the growth of the stents market during the forecast period from 2023-2028.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>B. Braun Launched Introcan Safety\u00ae 2 IV Catheter with Multi-Access Blood Control Designed to Protect Clinicians Every Time the Hub is Accessed On October 11, 2023, B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy, announced the launch of its new Introcan Safety\u00ae 2 IV Catheter with Multi-Access Blood Control.&nbsp; The most [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":25248,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[21357,21063,17113,3702,7396,21360,19352,20812,21355,704,21359,21358,2753,16975,420,21356,20461,18985,20071,20070,19484],"industry":[17226],"therapeutic_areas":[],"class_list":["post-25245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-anemocheck-home","tag-b-braun-medical","tag-biotronik","tag-chronic-kidney-disease","tag-chronic-kidney-disease-market","tag-contego-medical","tag-coronary-stents-market","tag-depuy-synthes","tag-everly-health","tag-fda","tag-hemoglobin-testing","tag-hemoglobin-testing-market","tag-medical-device","tag-medtech-market","tag-news","tag-sanguina","tag-spinal-cord-stimulation","tag-spinal-cord-stimulation-system","tag-spinal-surgery-devices","tag-spinal-surgery-devices-market","tag-stents","industry-medical-devices"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | B. Braun, Everly, Sanguina, Biotronik, Contego<\/title>\n<meta name=\"description\" content=\"B. Braun\u2019s Introcan Safety 2 IV Catheter; Sanguina\u2019s AnemoCheck; DePuy\u2019s TriALTIS\u2122 Spine System; Biotronik\u2019s Spinal Cord Stimulation Tech\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | B. Braun, Everly, Sanguina, Biotronik, Contego\" \/>\n<meta property=\"og:description\" content=\"B. Braun\u2019s Introcan Safety 2 IV Catheter; Sanguina\u2019s AnemoCheck; DePuy\u2019s TriALTIS\u2122 Spine System; Biotronik\u2019s Spinal Cord Stimulation Tech\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-12T11:15:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:44:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12163251\/medtech-news-for-everly-sanguina-biotronik.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | B. Braun, Everly, Sanguina, Biotronik, Contego","description":"B. Braun\u2019s Introcan Safety 2 IV Catheter; Sanguina\u2019s AnemoCheck; DePuy\u2019s TriALTIS\u2122 Spine System; Biotronik\u2019s Spinal Cord Stimulation Tech","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik","og_locale":"en_US","og_type":"article","og_title":"MedTech News | B. Braun, Everly, Sanguina, Biotronik, Contego","og_description":"B. Braun\u2019s Introcan Safety 2 IV Catheter; Sanguina\u2019s AnemoCheck; DePuy\u2019s TriALTIS\u2122 Spine System; Biotronik\u2019s Spinal Cord Stimulation Tech","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-10-12T11:15:34+00:00","article_modified_time":"2024-09-18T09:44:48+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12163251\/medtech-news-for-everly-sanguina-biotronik.webp","type":"image\/webp"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik","name":"MedTech News | B. Braun, Everly, Sanguina, Biotronik, Contego","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12163251\/medtech-news-for-everly-sanguina-biotronik.webp","datePublished":"2023-10-12T11:15:34+00:00","dateModified":"2024-09-18T09:44:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"B. Braun\u2019s Introcan Safety 2 IV Catheter; Sanguina\u2019s AnemoCheck; DePuy\u2019s TriALTIS\u2122 Spine System; Biotronik\u2019s Spinal Cord Stimulation Tech","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-everly-sanguina-biotronik#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12163251\/medtech-news-for-everly-sanguina-biotronik.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12163251\/medtech-news-for-everly-sanguina-biotronik.webp","width":772,"height":482,"caption":"MedTech News for Everly, Sanguina, Biotronik, Contego"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12163251\/medtech-news-for-everly-sanguina-biotronik-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AnemoCheck Home<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">B. Braun Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biotronik<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Kidney Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic kidney disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Contego Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Coronary Stents Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DePuy Synthes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Everly Health<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hemoglobin Testing<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hemoglobin Testing Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanguina<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Cord Stimulation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Cord Stimulation System<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Surgery Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Surgery Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Stents<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AnemoCheck Home<\/span>","<span class=\"advgb-post-tax-term\">B. Braun Medical<\/span>","<span class=\"advgb-post-tax-term\">Biotronik<\/span>","<span class=\"advgb-post-tax-term\">Chronic Kidney Disease<\/span>","<span class=\"advgb-post-tax-term\">chronic kidney disease market<\/span>","<span class=\"advgb-post-tax-term\">Contego Medical<\/span>","<span class=\"advgb-post-tax-term\">Coronary Stents Market<\/span>","<span class=\"advgb-post-tax-term\">DePuy Synthes<\/span>","<span class=\"advgb-post-tax-term\">Everly Health<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Hemoglobin Testing<\/span>","<span class=\"advgb-post-tax-term\">Hemoglobin Testing Market<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Sanguina<\/span>","<span class=\"advgb-post-tax-term\">Spinal Cord Stimulation<\/span>","<span class=\"advgb-post-tax-term\">Spinal Cord Stimulation System<\/span>","<span class=\"advgb-post-tax-term\">Spinal Surgery Devices<\/span>","<span class=\"advgb-post-tax-term\">Spinal Surgery Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Stents<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Oct 12, 2023","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Oct 12, 2023 4:45 pm","modified":"Updated on Sep 18, 2024 3:14 pm"},"featured_img_caption":"MedTech News for Everly, Sanguina, Biotronik, Contego","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25245"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25245\/revisions"}],"predecessor-version":[{"id":29625,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25245\/revisions\/29625"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25248"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25245"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25245"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}